JPS6251242B2 - - Google Patents
Info
- Publication number
- JPS6251242B2 JPS6251242B2 JP54129345A JP12934579A JPS6251242B2 JP S6251242 B2 JPS6251242 B2 JP S6251242B2 JP 54129345 A JP54129345 A JP 54129345A JP 12934579 A JP12934579 A JP 12934579A JP S6251242 B2 JPS6251242 B2 JP S6251242B2
- Authority
- JP
- Japan
- Prior art keywords
- bladder
- treatment
- active substance
- patients
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 claims description 18
- 239000013543 active substance Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 210000003205 muscle Anatomy 0.000 description 10
- 238000005259 measurement Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229930003347 Atropine Natural products 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 206010029446 nocturia Diseases 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010036018 Pollakiuria Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002921 anti-spasmodic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000014001 urinary system disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010048994 Bladder spasm Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000036724 intravesical pressure Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000005346 nocturnal enuresis Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000036318 urination frequency Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- UVKFSMBPRQBNCH-UHFFFAOYSA-M 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 UVKFSMBPRQBNCH-UHFFFAOYSA-M 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- KFUJMHHNLGCTIJ-UHFFFAOYSA-N Propiverine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CC[NH+](C)CC1 KFUJMHHNLGCTIJ-UHFFFAOYSA-N 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002236 emepronium Drugs 0.000 description 1
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical group C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 description 1
- 229960002493 emepronium bromide Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD78208336A DD139212A1 (de) | 1978-10-09 | 1978-10-09 | Verfahren zur herstellung eines neuen arzneimittels aus alpha,alpha-diphenyl-alpha-alkoxyessigsaeure-1-methylpiperidyl-4-ester-derivaten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5555117A JPS5555117A (en) | 1980-04-22 |
| JPS6251242B2 true JPS6251242B2 (pl) | 1987-10-29 |
Family
ID=5514770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12934579A Granted JPS5555117A (en) | 1978-10-09 | 1979-10-06 | Medicine for treating bladder in tension excess state |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5555117A (pl) |
| CH (1) | CH644016A5 (pl) |
| DD (1) | DD139212A1 (pl) |
| DE (1) | DE2937489A1 (pl) |
| GB (1) | GB2031727B (pl) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505717B2 (en) | 2012-01-30 | 2016-11-29 | Taiho Pharmaceutical Co., Ltd. | Acetic acid ester compound or salt thereof |
| US9718776B2 (en) | 2013-05-30 | 2017-08-01 | Taiho Pharmaceutical Co., Ltd. | Fluorinated benzilic acid ester compound and salt thereof |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3742580C1 (de) * | 1987-12-16 | 1989-05-11 | Schaper & Bruemmer Gmbh | Verwendung des alpha,alpha-Diphenyl-alpha-(3-carboxy-propionyloxy)-essigsaeure-4-(N-methylpiperidyl)-esters zur Behandlung hypertoner Funktionszustaende im Bereich der Harnblase |
| DE10129832A1 (de) * | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US7851633B2 (en) | 2006-06-09 | 2010-12-14 | Beiersdorf Ag | Piperidinium compounds and cosmetic compositions containing them |
| CN104302293B (zh) | 2012-05-15 | 2017-03-15 | 大鹏药品工业株式会社 | 用于压力性尿失禁的预防剂和/或治疗剂 |
-
1978
- 1978-10-09 DD DD78208336A patent/DD139212A1/xx unknown
-
1979
- 1979-09-17 DE DE19792937489 patent/DE2937489A1/de active Granted
- 1979-09-28 GB GB7933790A patent/GB2031727B/en not_active Expired
- 1979-10-05 CH CH900479A patent/CH644016A5/de not_active IP Right Cessation
- 1979-10-06 JP JP12934579A patent/JPS5555117A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505717B2 (en) | 2012-01-30 | 2016-11-29 | Taiho Pharmaceutical Co., Ltd. | Acetic acid ester compound or salt thereof |
| US9907792B2 (en) | 2012-01-30 | 2018-03-06 | Taiho Pharmaceutical Co., Ltd. | Acetic acid ester compound or salt thereof |
| US9718776B2 (en) | 2013-05-30 | 2017-08-01 | Taiho Pharmaceutical Co., Ltd. | Fluorinated benzilic acid ester compound and salt thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2937489A1 (de) | 1980-04-17 |
| CH644016A5 (de) | 1984-07-13 |
| DE2937489C2 (pl) | 1990-08-02 |
| DD139212A1 (de) | 1979-12-19 |
| GB2031727B (en) | 1982-11-03 |
| GB2031727A (en) | 1980-04-30 |
| JPS5555117A (en) | 1980-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050131049A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
| US20070270459A1 (en) | Overactive bladder treating drug | |
| Cardozo et al. | An objective comparison of the effects of parenterally administered drugs in patients suffering from detrusor instability | |
| KR100874815B1 (ko) | 간질성 방광염 치료용 의약 조성물 | |
| CA2001996C (en) | Method of treatment for interstitial cystitis | |
| Achong et al. | Fatal self-poisoning with lithium carbonate. | |
| JP2007517822A (ja) | 遺尿症を治療するためのアリール（またはヘテロアリール）アゾリルカルビノールの誘導体 | |
| Glickman et al. | Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study | |
| KR101971412B1 (ko) | 정맥 내 투여용 이부프로펜의 투여 | |
| JPS6251242B2 (pl) | ||
| KR100851938B1 (ko) | 방광 질환의 치료를 위한 카프-오피에이트 작용제 | |
| JP2549480B2 (ja) | 排尿障害改善剤 | |
| PT1965800E (pt) | Métodos de tratamento das incontinências | |
| Siris et al. | The problem of psychopharmacotherapy in the medically ill | |
| JP2000026313A (ja) | 消化管運動抑制剤 | |
| WO2024190894A1 (ja) | 排尿障害改善剤 | |
| Gray et al. | Urinary tract disorders | |
| US4755507A (en) | Method of treating benign prostatic hypertrophy | |
| EP1838313B1 (en) | Pharmaceutical composition comprising nifedipine and mesalazine for the treatment of rectoanal tenesmus | |
| UA146735U (uk) | Фармацевтичний препарат для лікування болю та запалення | |
| Popat et al. | BLADDER AND BOWEL DYSFUNCTION IN MULTIPLE SCLEROSIS: BETTER UNDERSTANDING AND MANAGEMENT. | |
| WO2000041728A1 (fr) | Compositions pour le traitement de la miction frequente et de l'incontinence d'urine | |
| EP0278165A2 (en) | Use of 3-benzazepines in the treatment of benign prostatic hypertrophy | |
| CZ290573B6 (cs) | Léčivo pro oąetřování inkontinence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |